Home/ Stocks/ CELC

Celcuity Inc. Common Stock

CELC XNAS

$131.06 +0.35 (+0.27%) ▲ 15-min delayed

Open

$130.71

High

$133.40

Low

$129.23

Volume

799.8K

Market Cap

$6.34B

About Celcuity Inc. Common Stock

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Sector: SERVICES-MEDICAL LABORATORIES Employees: 155 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-177,042,000	$-3.79
FY 2025	$0	$-177,042,000	$-3.79
Q3 2025	$0	$-43,804,000	$-0.92
Q2 2025	$0	$-45,268,000	$-1.04

Related Market News

No specific coverage for CELC yet. Check out our latest market news or earnings calendar.

Get CELC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Celcuity Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.